Global Hirschsprung’s Disease Treatment Market, By Type (Short-Segment Disease, Long-Segment Disease), Treatment (Surgery, Medication), Route of Administration (Oral, Parenteral, Others), End-Users (Clinics, Hospitals, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights: Global Hirschsprung’s Disease Treatment Market
Hirschsprung’s disease treatment market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a CAGR of 4.30% in the above-mentioned research forecast period. Rise in cardiovascular diseases and increasing prevalence of Hirschsprung’s disease worldwide.
Large number of associated anomalies including Down syndrome among others and rising diagnostic rate in order to achieve effective treatment also boost up the market growth. Moreover, increase in partnership and collaboration among market players and increasing government initiatives for maintaining better health of children population act as opportunity for the market growth. But, lack of definitive treatment options, misdiagnosis of disease, and limited access to health care services may hamper the global Hirschsprung’s disease treatment market.
Hirschsprung’s disease causes absence of nerves from some parts of the intestine. This disease is mostly diagnosed during development before birth, mostly identified during the first two months of life. Hirschsprung’s disease is further classified into two types depending upon the region of intestine which lacks the nerves. These two types include short-segment disease and long-term segment. In short-segment Hirschsprung’s disease nerves have been reported missing from only the last segment of large intestine while in long-segment Hirschsprung’s disease nerve cells are missing from most of the large intestine part. The most common types of Hirschsprung’s disease is short-segment disease and accounts for 80% of people suffering from Hirschsprung’s disease. However short-segment Hirschsprung’s disease affects only 20% of sufferers. Hirschsprung’s disease has been reported to occur with other types of disease combinations including Mowat-Wilson syndrome, Waardenburg syndrome or congenital central hypoventilation syndrome among others. Hirschsprung’s disease can be treated by medications including antibiotics, toxins among others. In severe cases surgical treatment suggested, however due to invasive nature most of the affected population prefers medication treatment approach.
The prevalence of Hirschsprung’s disease is increasing worldwide with reported prevalence of 1 in every 5,000 live births. Moreover this has also been reported that Hirschsprung’s disease is associated with several other complications including Down syndrome, dominant sensorineural deafness, Waardenburg syndrome, neurofibromatosis, neuroblastoma, ganglioneuroma, ganglioneuroblastoma, retinoblastoma, and tumors, which raises the demands of development of effective treatment approaches to deal with such and hence expected to provide market with the lucrative growth.
This Hirschsprung’s disease treatment market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Global Hirschsprung’s Disease Treatment Market Scope and Market Size
Hirschsprung’s disease treatment market is segmented on the basis of treatment, gender, route of administration, end-users and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of treatment, the Hirschsprung’s disease treatment market is segmented into surgery and medication. Medication segment is further sub-segmented into antibiotics, toxins and others. Antibiotics segment is further sub-segmented into ampicillin, gentamicin and metronidazole among others.
- On the basis of gender, the Hirschsprung’s disease treatment market is segmented into male and female.
- On the basis of route of administration, the Hirschsprung’s disease treatment market is segmented into oral, parenteral, others.
- On the basis of end-users, the Hirschsprung’s disease treatment market is segmented into pediatric clinics, hospitals, homecare, others.
- On the basis of distribution channel, the Hirschsprung’s disease treatment market has also been segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy, others.
Hirschsprung’s Disease Treatment Market Country Level Analysis
Hirschsprung’s disease treatment market is analysed and market size information is provided by country, treatment, gender, route of administration, end-users and distribution channel as referenced above.
The countries covered in the Hirschsprung’s disease treatment market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.
On geographical estimation, North America accounts the largest market share due to rise in prevalence of Hirschsprung’s disease in U.S, as approximately 1 in every 5400-7200 new borns are affected. Moreover adoption of various treatment modalities is another factor driving the market growth. Europe accounts the second largest market share due to wide drug distribution network and growing awareness towards intestinal diseases. Asia-Pacific is expected to account for the largest market share over coming years for the Hirschsprung’s disease treatment market due to continuous development in health and pharmaceutical industries and rising investment in emerging economies.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Hirschsprung’s disease treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Hirschsprung’s Disease Treatment Market Share Analysis
Hirschsprung’s disease treatment market competitive landscape provides details by competitor, details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to Hirschsprung’s disease treatment market.
The major players covered in the Hirschsprung’s disease treatment market are Pfizer Inc., Sanofi, Johnson & Johnson Services, Inc., Novartis AG, Merck KGaA, Bristol-Myers Squibb, Astellas Pharma, Inc., Eli Lilly and Company, Abbott, Panacea Biotech Ltd., Cipla Ltd., GlaxoSmithKline, Dr. Reddy’s Laboratories Ltd., Baxter International, Wuhan Wuyao Pharmaceutical Co.,ltd, Hubei Hongyuan Pharmaceutical technology Co.,Ltd., CordenPharma International, AbbVie among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-
